These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34277971)

  • 41. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
    Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
    J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
    Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL
    J Am Heart Assoc; 2023 Jul; 12(13):e028516. PubMed ID: 37345834
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR).
    Weir MR; Kline I; Xie J; Edwards R; Usiskin K
    Curr Med Res Opin; 2014 Sep; 30(9):1759-68. PubMed ID: 24786834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
    Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B
    Diabetes Obes Metab; 2020 Oct; 22(10):1753-1766. PubMed ID: 32436638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis.
    Feng KY; Li J; Ianus J; de Zeeuw D; Fulcher GR; Pfeifer M; Matthews DR; Jardine MJ; Perkovic V; Neal B; Mahaffey KW
    Diabetes Obes Metab; 2021 Dec; 23(12):2707-2715. PubMed ID: 34402161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
    Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL
    Diabetes Care; 2022 Nov; 45(11):2644-2652. PubMed ID: 36134918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program.
    Arnott C; Neuen BL; Heerspink HJL; Figtree GA; Kosiborod M; Lam CS; Cannon CP; Rosenthal N; Shaw W; Mahaffey KW; Jardine MJ; Perkovic V; Neal B
    Int J Cardiol; 2020 Nov; 318():126-129. PubMed ID: 32569700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Law G; Desai M; Matthews DR;
    N Engl J Med; 2017 Aug; 377(7):644-657. PubMed ID: 28605608
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Canagliflozin: A Review in Type 2 Diabetes.
    Deeks ED; Scheen AJ
    Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
    Sen T; Koshino A; Neal B; Bijlsma MJ; Arnott C; Li J; Hansen MK; Ix JH; Heerspink HJL
    Diabetes Obes Metab; 2022 Oct; 24(10):1950-1956. PubMed ID: 35635326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.
    Li J; Woodward M; Perkovic V; Figtree GA; Heerspink HJL; Mahaffey KW; de Zeeuw D; Vercruysse F; Shaw W; Matthews DR; Neal B
    JACC Heart Fail; 2020 Jan; 8(1):57-66. PubMed ID: 31676303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
    Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
    Vaduganathan M; Sattar N; Xu J; Butler J; Mahaffey KW; Neal B; Shaw W; Rosenthal N; Pfeifer M; Hansen MK; Januzzi JL
    J Am Coll Cardiol; 2022 Feb; 79(5):432-444. PubMed ID: 35115099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.